C. Fowst

发表

Brostallicin: a new concept in minor groove DNA binder development

M. Broggini, E. Fontana, S. Marchini, 2004, Anti-cancer drugs.

Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells

S. Marchini, J. Tursi, A. Fedier, 2003, British Journal of Cancer.

Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.

M. Del Vecchio, L. Rimassa, A. Anichini, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.

L. Dirix, M. Kaufmann, S. Jones, 2000, Clinical breast cancer.

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

P. Lønning, N. Aaronson, M. Tubiana-Hulin, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.

L. Dirix, M. Kaufmann, S. Jones, 2000, European journal of cancer.

Activity o f E xemestane i n M etastatic B reast C ancer After F ailure o f N onsteroidal A romatase I nhibitors: A P hase I I T rial

N. Aaronson, M. Mita, A. Polli, 2000 .

Bleeding time and antiplatelet agents in normal volunteers

E. Pogliani, G. Corneo, C. Fowst, 1992, International journal of clinical & laboratory research.

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.

Suzanne F. Jones, H. Burris, J. Infante, 2011, European journal of cancer.

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.

C. Burton, J. Radford, A. Santoro, 2021, Blood advances.

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

R. Motzer, J. Larkin, R. Motzer, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck.

U. Pastorino, R. Dittadi, M. Gion, 2003, European journal of cancer.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

J. Larkin, T. Powles, T. Choueiri, 2018, The Lancet. Oncology.

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

L. Dirix, M. Kaufmann, Stephen E. Jones, 1999 .

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.

Craig B. Davis, T. Powles, S. Park, 2020, The New England journal of medicine.

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

R. Finn, Marcus Schmidt, I. Bondarenko, 2017 .

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo

L. Collette, D. Lacombe, L. Seymour, 2014, European journal of cancer.

A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors

J. Berlin, A. Lockhart, E. Fontana, 2004, Clinical Cancer Research.

A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors

J. Berlin, A. Lockhart, E. Fontana, 2004, Clinical Cancer Research.

Effects of a Defibrotide—Heparin Combination on Some Measures of Haemostasis in Healthy Volunteers

R. Girardello, E. Pogliani, C. Fowst, 1989, The Journal of international medical research.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Xin Huang, Johannes Ettl, Marcus Schmidt, 2015, The Lancet. Oncology.

Updated ef ﬁ cacy results from the JAVELIN Renal 101 trial: ﬁ rst-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

R. Motzer, M. Grimm, M. B. Atkins, 2020 .

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

L. Dirix, M. Kaufmann, Stephen E. Jones, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Blay, M. van Glabbeke, J. Verweij, 2007, European journal of cancer.

CNS Metastasis in Ovarian Cancer with Microangiopathic Hemolytic Anemia Associated with Diffuse Intravascular Coagulation

E. Pogliani, C. Fowst, E. Polli, 1988, Tumori.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

R. Motzer, J. Larkin, T. Choueiri, 2019, The New England journal of medicine.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

J. Dering, R. Finn, D. Slamon, 2009, Breast Cancer Research.

Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

R. Finn, N. Shaik, J. Glaspy, 2009 .

Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin® (exemestane), in advanced breast cancer patients having progressed on antiestrogens

M. Kaufmann, Stephen E. Jones, A. Polli, 1999 .

Platelet dysfunction in acute megakaryoblastic leukemia.

M. Colombi, E. Cofrancesco, E. Pogliani, 1989, Acta haematologica.

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

L. Paz-Ares, A. Szczesna, J. Schiller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Rizzoli, R. Fanin, M. Baccarani, 1993, Leukemia & lymphoma.

A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients

R. Fanin, M. Baccarani, E. Morra, 1992 .

Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results

Suzanne F. Jones, H. Burris, J. Infante, 2008 .

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Brostallicin ( PNU-166196 ) , a New DNA Minor-Groove Binder , Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer 1

J. Verweij, A. Sparreboom, F. Fiorentini, 2003 .

Cerebral parenchymal involvement in acute promyelocytic leukemia. A case report.

E. Pogliani, C. Fowst, E. Polli, 1988, Haematologica.

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, H. Burris, J. Infante, 2008 .

Heparin-induced platelet aggregation and its inhibition by antagonists of the thromboxane pathway.

M. Colombi, E. Cofrancesco, E. Pogliani, 1986, Thrombosis research.